© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
124991 |
As an accredited 5-Bromo-4-Fluoro-1H-Indazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 5-Bromo-4-Fluoro-1H-Indazole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
After years of watching the field of organic synthesis shift to meet new demands, I’ve seen certain specialty chemicals set benchmarks for reliability, versatility, and impact. 5-Bromo-4-Fluoro-1H-Indazole belongs in that league. Chemists searching for selective halogenation and high-purity heterocycles often navigate a crowded catalog of molecules, each promising something special. Some deliver; others simply take up shelf space. This compound manages to fill a clear need in both pharmaceutical development and chemical research, earning its place on lab benches worldwide.
Researchers have been demanding ever-stricter controls over impurities, seeking lot-to-lot consistency not just in theory but in actual hands-on practice. 5-Bromo-4-Fluoro-1H-Indazole, with its typical chemical formula C7H3BrFN2, delivers on these expectations. Reliable sources provide this compound with purity levels often above 98%, tested by HPLC or NMR, which means less time worrying about contaminants and more time exploring real results.
A molecular weight in the range of 215-220 g/mol puts it comfortably in the territory that supports further derivatization without weighing down reaction pathways. The crystalline, off-white solid form offers straightforward handling—no unusual storage quirks, no unpleasant volatility under standard laboratory conditions. Organofluorine and organobromine chemistries require this kind of tactile predictability.
It resists decomposition under routine ambient conditions, showing a solid shelf life when secured in the usual desiccators or refrigerators. From years of personal lab work, cutting down on unexpected material loss keeps budgets tighter and timelines shorter. Nobody wants to repeat a months-long synthesis because a key intermediate spoiled on the shelf.
The world isn’t exactly short on indazole derivatives. Recognizing what sets 5-Bromo-4-Fluoro-1H-Indazole apart means looking at its twin halide substitutions—bromine and fluorine—positioned smartly on the indazole ring. Unlike classical derivatives with either a single halogen or mixed substitutions in less reactive sites, this molecule provides a precise entry point for selective cross-coupling and functional group transformations. Copper- and palladium-catalyzed couplings are more than just theoretical possibilities; they become reliable tools enabled by this structure.
Medicinal chemists trying to prepare new kinase inhibitors or small-molecule probes regularly appreciate the push toward structural diversity offered here. Electrophilic aromatic substitution and nucleophilic aromatic substitution become practical, not just possible, thanks to the electron-withdrawing interplay between bromine and fluorine. Synthetic routes that used to be time-consuming gain new efficiency.
Comparison with mono-halogenated indazoles tells the story best. If you’ve ever tried to push forward a Suzuki-Miyaura coupling with only a bromine at the C-5 position, you’ve probably noticed sluggish reaction rates, occasional overreactions, or drift in selectivity. Introduce fluorine at the C-4 position, as in this compound, and those difficulties begin fading. The electron environment stabilizes the ring, enhances regioselectivity, and limits unwanted side reactions. This is not the sort of advantage that shows up in glossy brochures—it comes out when you’re measuring yields and checking spectra.
Other multi-halogenated indazoles frequently run into steric hindrance or unpredictable reactivity, making scale-up tricky. Here, the compact design of the molecule steers reactions down familiar, interpretable paths. Over the years, this difference becomes clear in less wasted material, fewer purification headaches, and more reliable reporting of results.
Therapeutic development teams consistently work under pressure to deliver candidates ready for animal testing, high-throughput screening, and later, clinical trials. The right building blocks streamline this process. Many indazole derivatives have featured in kinase inhibitors, anti-inflammatory agents, and oncology drugs. What 5-Bromo-4-Fluoro-1H-Indazole offers is a scaffolding that enables rapid diversification in SAR (structure–activity relationship) studies—essentially, it helps map out which molecular tweaks drive up potency, improve selectivity, or reduce side effects.
Drug designers often run up against metabolic instability or off-target effects from poorly chosen halogen positions. This compound’s layout sidesteps many of those issues, supporting analogs with optimized metabolic profiles. That’s the kind of edge that makes the difference between a promising molecule and a dead end.
Few working in today’s labs ignore the push toward greener chemistry. Sourcing raw materials, minimizing waste, and streamlining reaction steps all matter. I’ve watched the transition from heavy reliance on toxic solvents toward more sustainable processes. 5-Bromo-4-Fluoro-1H-Indazole stands out because it can be synthesized in relatively short, efficient steps, frequently in moderate to high yields, and often avoids noxious reagents. Most preparation routes involve selective bromination and fluorination of indazole cores, managed under controlled settings.
Less byproduct means lower costs in waste management. Fewer purification stages shrink solvent use. As regulatory pressure grows—look at recent European Union guidelines or the demands from U.S. pharmaceutical watchdogs—products like this ease compliance. The desire to move away from legacy intermediates riddled with hazardous contaminants keeps this molecule in demand.
Every skilled organic chemist I know reads synthetic pathways with a careful eye for pitfalls. 5-Bromo-4-Fluoro-1H-Indazole was almost built for modern cross-coupling methods. The bromine facilitates reactions at C-5, opening doors to Suzuki, Buchwald-Hartwig, or Heck reactions. The fluorine, less bulky and highly electronegative, controls activation at C-4, shielding it from unwanted nucleophiles yet supporting subsequent substitutions with the right catalysts.
In practical terms, the routes enabled by this combination mean quick access to arylated, alkylated, or even heteroaryl indazoles, all using standard, scalable procedures. Those working on iterative analog synthesis will find this particularly liberating—a wider array of functional groups can be introduced without elaborate protecting group strategies.
The molecule’s behavior under a range of pH and solvent systems remains cooperative. Experienced hands rarely report surprises—no unexpected tars, no mystery side products, no stubborn insolubility with standard organic solvents like DMF, DMSO, or acetonitrile.
Nobody should overlook safety, and this chemistry doesn’t tend to generate headlines in incident reports. Like most halogenated aromatics, 5-Bromo-4-Fluoro-1H-Indazole demands basic caution—proper gloves, safety shields, ventilation—but nothing extraordinary compared to the arsenal of far more hazardous reagents. Disposal matches standard protocols for organic halides, supporting safer operations from bench scale through pilot plant.
Many users—young researchers, pharmaceutical process engineers, industrial chemists—appreciate the predictable physical form. No suddenly reactive dust clouds or sneaky exotherms. It packs easily, ships reliably, and doesn’t require elaborate quenching procedures at workup.
Graduate students under tight timelines often experiment with novel kinase inhibitors or anti-infective agents. The success rate with indazole derivatives depends strongly on molecular flexibility and the ease of downstream functionalization. Case after case in published literature shows enhanced selectivity and biological activity from precisely substituted indazole cores—including those with bromine and fluorine at these positions.
In one reported project focused on oncogenic kinase inhibitors, introducing the 5-bromo-4-fluoro motif allowed for stronger binding affinity with the ATP pocket. Test compounds not only moved through biological screening faster but also provided cleaner separation profiles. This isn’t unique to cancer research—similar advantages arise in neuropharmacology, infectious diseases, and inflammation models. Every researcher who saves weeks at the “hit modification” stage understands the practical difference brought by a smartly designed scaffold.
The gulf between milligram-scale discovery and kilogram-scale production remains one of the oldest headaches in process chemistry. Many students succeed in synthesizing a new compound at tiny yield in a university lab, only to discover the real pain comes later, when scale-up reveals hidden costs or technical barriers. 5-Bromo-4-Fluoro-1H-Indazole avoids many of these traps. Its synthesis doesn’t rely on hard-to-source precursors or exotic catalysts. Batch and flow processes alike support clean conversion to the target structure.
Routine monitoring by NMR, IR, and LC/MS confirms purity and structure, removing doubts as projects move forward. Documentation is straightforward, matching both GMP (Good Manufacturing Practice) and non-clinical research lab standards. This means faster tech transfer and less confusion across regulatory audits. Realistically, nearly every process chemist prefers intermediates and building blocks that don’t require endless adaptation or emergency troubleshooting.
Price always matters, especially as funding streams tighten and project managers hunt for every possible efficiency. The combination of robust, high-yield synthesis with minimal waste makes 5-Bromo-4-Fluoro-1H-Indazole cost-competitive. Institutions buying for medicinal chemistry programs see their budgets stretch further—not only because of lower purchase cost per gram, but also thanks to greater reliability in downstream transformations.
Suppliers have responded to rising demand with improved packaging and distribution logistics, avoiding supply chain bottlenecks so familiar with niche specialty chemicals. Happily, this helps keep timelines predictable and project planners satisfied.
Relying on a well-characterized compound frees up time to focus on what matters: the hypotheses to be tested, the reactions to be run, and the biological assays to interpret. 5-Bromo-4-Fluoro-1H-Indazole has transitioned seamlessly from the shelves of specialty chemical suppliers into the daily workflow of cutting-edge drug discovery, material science, and academic research.
Over the years, the sharpest projects I’ve watched tended to build in two things: the right scientific question, and the right molecular tools. Contributing a stable, adaptable, halogenated indazole to the experiment provides more flexibility and fewer surprises along the way. It’s this reliability, not abstract phrases or shiny product listings, that separates the memorable projects from the meandering ones.
Chemistry never stands still. As new catalytic strategies and late-stage functionalization approaches arrive, the demand for specialty building blocks grows larger. The next wave of pharmaceuticals could well depend on rapid, iterative variant synthesis around robust scaffolds like 5-Bromo-4-Fluoro-1H-Indazole. The lessons learned at the bench—workability, selectivity, stability—will shape which compounds make the leap from idea to real-world impact.
Continuous dialogue between synthetic chemists, analytical teams, and regulatory groups gives research-grade indazole derivatives their special status. By picking a well-tried, well-documented intermediate, today’s teams get a head start against tomorrow’s scientific challenges. Every day spent refining the small details in synthesis pays off tenfold later in increased confidence and project speed.
Every research group faces setbacks. Late-stage impurities, slow reaction rates, or stubborn solubility issues can derail months of work. Purposefully engineered small molecules are part of the answer. 5-Bromo-4-Fluoro-1H-Indazole is a prime example: it streamlines reaction design and lifts a burden from purification and analysis teams.
Expanding access to high-purity, well-documented compounds brings another, subtler improvement: it lets rising researchers focus on genuine innovation instead of re-running failed chromatography or chasing down unpredictable side products. Instead of patching over process weaknesses with endless troubleshooting, attention shifts toward building knowledge, refining techniques, and making new discoveries.
One of the best decisions for resource-strapped university labs, fast-moving biotech startups, and established pharmaceutical giants alike rests in the selection of chemicals that give proven, reproducible results. As I’ve seen countless times, even the most talented teams end up frustrated by inconsistent supplies or unwelcome surprises in their starting materials. Investing in quality saves both money and morale.
Trust accumulates over years, lab by lab, project by project. 5-Bromo-4-Fluoro-1H-Indazole has built a reputation beyond marketing promise, cemented by the quiet successes of thousands of reactions checked and rechecked in dozens of settings. In scientific research, trustworthy compounds become the foundation for bolder explorations—less time repeating the basics, more time at the frontiers.
And as today’s drug challenges grow more complex and the margin for error narrows, demands for quality and consistency only increase. Thoughtful selection of starting points—shaped by deep technical understanding and honest observation—remains the hidden backbone of progress.
Looking ahead, the field’s appetite for new structures keeps rising. Technologies such as accelerated screening, AI-directed chemical synthesis, and bespoke material design need trusted platforms. 5-Bromo-4-Fluoro-1H-Indazole, with its clear history of dependability and adaptability, is positioned to keep contributing in labs that rethink the old and invent the new.
Each cycle of improvement—pure starting materials, shorter syntheses, fewer side reactions—drives cost down and opens creative doors for researchers. History suggests those benefits don’t just stay with the researcher who first picks up a vial; they filter outward, speeding up the whole scientific ecosystem.
After years inside the laboratory and at the whiteboard, watching ideas shift from possibility to achievement, my view is clear. Products like 5-Bromo-4-Fluoro-1H-Indazole demonstrate the difference between theoretical potential and real-world results. Reliable molecular building blocks—the unsung heroes of modern research—let each generation push boundaries further. As more projects pursue targeted, efficient syntheses and demand uncompromising purity, expect this compound to keep turning up at the root of tomorrow’s discoveries.
Researchers don’t always need the fanciest new reagent; they need the ones that work, time after time, so they can spend their energy where it counts. In that sense, this halogenated indazole stands out not for complexity, but for all the ways it makes hard work a little less hard. It’s a difference noticed not just in yield, but in every successful step forward that chemistry, in the right hands, can bring.
